Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Degenerative diseases are a major public health concern for the aging population and mesenchymal stem cells (MSCs) have great potential for treating many of these diseases. However, the quantity and quality of MSCs declines with aging, limiting the potential efficacy of autologous MSCs for treating the elderly population.

Methods: Human bone marrow (BM)-derived MSCs from young and elderly donors were obtained and characterized using standard cell surface marker criteria (CD73, CD90, CD105) as recommended by the International Society for Cellular Therapy (ISCT). The elderly MSC population was isolated into four subpopulations based on size and stage-specific embryonic antigen-4 (SSEA-4) expression using fluorescence-activated cell sorting (FACS), and subpopulations were compared to the unfractionated young and elderly MSCs using assays that evaluate MSC proliferation, quality, morphology, intracellular reactive oxygen species, β-galactosidase expression, and adenosine triphosphate (ATP) content.

Results: The ISCT-recommended cell surface markers failed to detect any differences between young and elderly MSCs. Here, we report that elderly MSCs were larger in size and displayed substantially higher concentrations of intracellular reactive oxygen species and β-galactosidase expression and lower amounts of ATP and SSEA-4 expression. Based on these findings, cell size and SSEA-4 expression were used to separate the elderly MSCs into four subpopulations by FACS. The original populations (young and elderly MSCs), as well as the four subpopulations, were then characterized before and after culture on tissue culture plastic and BM-derived extracellular matrix (BM-ECM). The small SSEA-4-positive subpopulation representing ~ 8% of the original elderly MSC population exhibited a "youthful" phenotype that was similar to that of young MSCs. The biological activity of this elderly subpopulation was inhibited by senescence-associated factors produced by the unfractionated parent population. After these "youthful" cells were isolated and expanded (three passages) on a "young microenvironment" (i.e., BM-ECM produced by BM cells from young donors), the number of cells increased ≈ 17,000-fold to 3 × 10 cells and retained their "youthful" phenotype.

Conclusions: These results suggest that it is feasible to obtain large numbers of high-quality autologous MSCs from the elderly population and establish personal stem cell banks that will allow serial infusions of "rejuvenated" MSCs for treating age-related diseases.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658952PMC
http://dx.doi.org/10.1186/s13287-017-0688-xDOI Listing

Publication Analysis

Top Keywords

elderly mscs
20
young elderly
16
elderly
12
mscs
12
ssea-4 expression
12
quantity quality
8
mesenchymal stem
8
stem cells
8
autologous mscs
8
mscs treating
8

Similar Publications

To compare the efficacy of using bone marrow mesenchymal stem cell (BM-MSC) exosomes and injectable platelet rich fibrin (i-PRF) on the submandibular salivary glands (SMGs) of aged albino rats in restoring salivary gland structure and function. A total of 40 healthy male albino rats were used, two for obtaining the BM-MSCs, 10 for i-PRF preparation and seven adult rats (6-8 months old) represented the control group (Group 1). The remaining 21 rats were aged (18-20 months old) and divided into three groups of seven rats each; (Group 2): received no treatment, (Group 3): each rat received a single intraglandular injection of BM-MSC exosomes (50 μg/kg/dose suspended in 0.

View Article and Find Full Text PDF

Background: The objective of this study was to assess the long-term effectiveness and safety of implanting mesenchymal stem cells derived from umbilical cord tissue (UC-MSC) in patients diagnosed with retinitis pigmentosa (RP).

Methods: In this single-center study with a retrospective design, 669 eyes received suprachoroidal implantation of 5 million UC-MSCs. Postoperative assessments were conducted on the first day, third month, and every 6 months thereafter.

View Article and Find Full Text PDF

Proinflammatory Effect of Mesenchymal Stem Cells From Patients With Multiple Sclerosis: Potential Modulation Targets.

Neurol Neuroimmunol Neuroinflamm

November 2025

Department of Neurology, Nottingham Centre for MS and Neuroinflammation, Queen's Medical Centre, Nottingham University Hospitals NHS Trust, United Kingdom.

Background And Objectives: Mesenchymal stem cells (MSCs) represent a potential cellular therapy for multiple sclerosis (MS). It has been suggested that MSCs from patients with MS have lower immunomodulatory properties than those from healthy controls (HCs). The aims of this study were to compare the immunomodulatory abilities of MSCs from patients with MS and HCs against autologous immune cells and to identify potential targets affecting this ability.

View Article and Find Full Text PDF

Background: Bone mesenchymal stem cells (BMSCs) from patients with diabetes often exhibit reduced osteogenic potential. This study aimed to investigate the mechanism of action of G9a, known as euchromatic histone lysine methyltransferase 2 (EHMT2), identify its key responsive long non-coding RNA in diabetic osteoporosis (DOP), and evaluate the effectiveness of the G9a inhibitor (UNC0638).

Methods: The expression level of G9a in bone-derived MSCs (BMSCs) from osteoporosis patients with or without T2DM (T2DM-BMSCs, CON-BMSCs) was detected, and osteogenic differentiation was evaluated by osteogenic genes, ALP activity and calcification level.

View Article and Find Full Text PDF

Worldwide, more than 4 million patients with end-stage kidney disease require hemodialysis through an arteriovenous fistula (AVF). AVFs fail because of venous neointimal hyperplasia (VNH) resulting in venous stenosis formation. A phase 1 randomized trial in patients undergoing upper extremity AVF placement was performed to evaluate the safety and efficacy of autologous adipose-derived mesenchymal stem cells (MSCs) in improving AVF function.

View Article and Find Full Text PDF